Lakefront Biotherapeutics NV (MEX:GLPGN) Stock Based Compensation: MXN0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:GLPGN Lakefront Biotherapeutics NV MEX:GLPGN
58 GF Score
Price MXN665.65
GF Value MXN3,143.44
! 4 Warning Signs
View Full Analysis

What is Lakefront Biotherapeutics NV Stock Based Compensation?

Lakefront Biotherapeutics NV MEX:GLPGN 58 Stock Based Compensation is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:GLPGN with a GF Score™ of 58/100 and a GF Value™ of MXN3,143.44. The stock has 4 warning signs investors should review.

Lakefront Biotherapeutics NV's Stock Based Compensation for the three months ended in Mar. 2026 was MXN0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was MXN0 Mil.

Lakefront Biotherapeutics NV Stock Based Compensation Related Terms

Lakefront Biotherapeutics NV Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Lakefront Biotherapeutics NV's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakefront Biotherapeutics NV Stock Based Compensation Chart

Lakefront Biotherapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,639.41 1,827.87 1,049.89 434.28 505.99

Lakefront Biotherapeutics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:GLPGN
58GF Score
Lakefront Biotherapeutics NV MEX:GLPGN
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakefront Biotherapeutics NV Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

What does a Stock Based Compensation of MXN0 Mil mean?
Lakefront Biotherapeutics NV (MEX:GLPGN) has a Stock Based Compensation of MXN0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Lakefront Biotherapeutics NV and its competitors.
Is Lakefront Biotherapeutics NV's Stock Based Compensation too high?
Lakefront Biotherapeutics NV's current Stock Based Compensation is MXN0 Mil. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's Stock Based Compensation compare to VRTX and REGN?
Lakefront Biotherapeutics NV's Stock Based Compensation of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Lakefront Biotherapeutics NV and its competitors. Lakefront Biotherapeutics NV's current Stock Based Compensation is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Lakefront Biotherapeutics NV (MEX:GLPGN) has a current Stock Based Compensation of MXN0 Mil. The stock's GF Value™ is MXN3,143.44, compared to a current price of MXN665.65 — trading 78.8% below its estimated fair value. The current Stock Based Compensation is MXN0 Mil. Lakefront Biotherapeutics NV's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (MEX:GLPGN), the current Stock Based Compensation is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lakefront Biotherapeutics NV (MEX:GLPGN) Overvalued in 2026?

Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued. The current stock price of MXN665.65 is trading 78.8% below its estimated GF Value™ of MXN3,143.44.

Key valuation signals for MEX:GLPGN:

  • Stock Based Compensation: MXN0 Mil
  • GF Value™: MXN3,143.44 vs. price of MXN665.65 (78.8% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the MEX:GLPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lakefront Biotherapeutics NV Business Description

Address Schalienhoevedreef 20 T, Mechelen, BEL, 2800
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
58GF Score

Get the complete analysis for MEX:GLPGN

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN665.65
Price
MXN3,143.44
GF Value